Oculis (NASDAQ:OCS) Sees Large Volume Increase – Here’s Why

Shares of Oculis Holding AG (NASDAQ:OCS) saw unusually-strong trading volume on Wednesday . Approximately 70,058 shares were traded during mid-day trading, a decline of 38% from the previous session’s volume of 112,347 shares.The stock last traded at $18.55 and had previously closed at $18.22.

Analyst Ratings Changes

A number of analysts have commented on the stock. Chardan Capital reaffirmed a “buy” rating and set a $28.00 target price on shares of Oculis in a report on Tuesday. HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Oculis in a report on Monday. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Oculis has a consensus rating of “Buy” and an average target price of $28.80.

Oculis Stock Up 1.1 %

The company has a quick ratio of 4.02, a current ratio of 4.02 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $746.08 million, a PE ratio of -9.54 and a beta of -0.33. The stock has a 50-day simple moving average of $16.35 and a 200-day simple moving average of $13.84.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.